Cavernomas and Epilepsy

How a vascular malformation can become part of a focal epileptic network

A cerebral cavernous malformation — often called a cavernoma, cavernous malformation or cavernous angioma — is a cluster of abnormally formed, thin-walled blood vessels within the brain. Some are discovered incidentally and never cause symptoms. Others can bleed, produce focal neurological symptoms, cause headaches or become associated with epileptic seizures.

When seizures arise because of a cavernoma, clinicians may use the term cavernous malformation-related epilepsy. This is usually a focal epilepsy because the seizure-generating network develops in relation to a particular brain region rather than the whole brain at once.

The presence of a cavernoma on MRI does not automatically prove that it is causing a person’s seizures. Location, seizure semiology, EEG findings, MRI features, the number of cavernomas and the wider clinical picture all matter.

Why can a cavernoma cause seizures?

The cavernoma itself is not made of normal functioning brain tissue. Seizures are thought to arise largely from changes in the surrounding brain.

Cavernomas can leak very small amounts of blood over time. Breakdown products from blood, particularly iron-containing haemosiderin, may accumulate around the lesion. Repeated microhaemorrhage can be accompanied by gliosis, inflammation and changes in the excitability of nearby cortex.

These processes can make surrounding neurons more likely to participate in abnormal synchronous electrical activity. In other words, the visible vascular lesion can help create an epileptogenic environment around itself.

This also explains why the seizure-generating tissue may extend beyond the exact border of the cavernoma seen on MRI.

Location matters

Cavernoma-related epilepsy is much more strongly associated with supratentorial lesions — cavernomas in the cerebral hemispheres — than with lesions confined to the brainstem or spinal cord.

Cortically located cavernomas are particularly relevant because seizures arise from cerebral cortical networks. Temporal lobe cavernomas are especially associated with epilepsy, although frontal, parietal and occipital cavernomas can also generate seizures.

The seizure manifestations depend on the network involved. A temporal cavernoma might be associated with altered awareness, experiential symptoms, fear, automatisms or sensory phenomena. A frontal lesion may produce tonic or hypermotor features. A cavernoma involving motor cortex may cause focal jerking, while occipital involvement can produce visual symptoms.

Symptoms alone cannot prove which lesion is responsible, especially when somebody has more than one cavernoma.

One cavernoma or many?

Some people have a single sporadic cavernous malformation. Others have familial cerebral cavernous malformation, in which multiple lesions can occur and new lesions may develop over time.

Familial disease can be associated with pathogenic variants involving KRIT1 (CCM1), CCM2 or PDCD10 (CCM3). Genetic counselling and testing may be considered when the pattern of disease suggests an inherited form.

Multiple cavernomas create an additional diagnostic problem: finding several lesions on MRI does not tell clinicians which one, if any, is producing the seizures.

That is why the current consensus guideline recommends neurological assessment and EEG when the relationship between a cavernoma and the seizures is uncertain, particularly when multiple lesions are present and surgery is being considered.

A first seizure can matter differently here

In definite cavernous malformation-related epilepsy, the risk of further seizures after a first unprovoked seizure is high. The 2025/2026 consensus guideline reports evidence that recurrence risk is sufficiently high for antiseizure medication to be recommended after a first seizure believed to be caused by a cavernous malformation.

This is different from saying that every person with a cavernoma should take antiseizure medication.

An incidental cavernoma in somebody who has never had a seizure is not, by itself, an indication for antiseizure treatment. Treatment is directed at the clinical problem actually present.

How is cavernoma-related epilepsy diagnosed?

Diagnosis usually combines several forms of evidence:

the history of the events;
witness descriptions or video where available;
seizure semiology;
MRI showing the cavernous malformation and surrounding changes;
EEG, particularly when the relationship between symptoms and the lesion is uncertain;
sometimes prolonged ambulatory EEG or inpatient video-EEG;
the anatomical relationship between the lesion and the suspected seizure-onset network.

A normal routine EEG does not exclude cavernoma-related epilepsy. Conversely, an abnormal EEG does not automatically prove that a particular cavernoma is the cause.

What does a cavernoma look like on MRI?

MRI is the key imaging technique for detecting and characterising cerebral cavernous malformations. Their appearance reflects blood products at different stages and can be particularly conspicuous on susceptibility-sensitive sequences.

Sequences such as susceptibility-weighted imaging can reveal small lesions and haemosiderin that may not be obvious on conventional sequences.

The imaging appearance is useful for diagnosis, but MRI still shows structure rather than directly recording seizure onset. See also MRI Lesion Does Not Always Mean Seizure Cause.

Does bleeding cause the seizures?

Sometimes a clinically significant haemorrhage may be associated with new neurological symptoms or seizures, but cavernoma-related epilepsy does not require a large symptomatic brain haemorrhage.

Repeated microscopic leakage and deposition of blood-breakdown products around the lesion are thought to contribute to epileptogenesis even when there has been no dramatic recognised bleed.

This is why the seizure history and the haemorrhage history are related but not interchangeable.

Antiseizure medication

For a first seizure believed to be caused by a cavernoma, current consensus guidance recommends antiseizure medication as an appropriate initial treatment.

The specific medicine is chosen using the same broad principles applied elsewhere in focal epilepsy: seizure type, age, other illnesses, pregnancy considerations where relevant, psychiatric and cognitive effects, kidney and liver function, other medications and individual tolerability.

There is no single drug that is uniquely correct for cavernoma-related epilepsy.

Published cohorts suggest that a substantial proportion of people can achieve seizure freedom with medication, but a meaningful minority develop drug-resistant epilepsy.

When does drug resistance matter?

Drug-resistant epilepsy is generally defined by the ILAE as failure of two appropriately chosen, adequately used and tolerated antiseizure medication schedules to achieve sustained seizure freedom.

When this happens in somebody with a cavernoma that plausibly relates to the seizures, specialist epilepsy-surgery assessment becomes especially important.

Persistent seizures should not simply lead to an endless sequence of medication changes without reconsidering whether the structural lesion can be treated directly.

Can surgery cure the epilepsy?

Surgery can produce very good seizure outcomes in appropriately selected people with cavernoma-related epilepsy, particularly when the cavernoma is superficial, surgically accessible and clearly concordant with the seizure network.

The current consensus guideline reports substantially better seizure-freedom outcomes in some surgical series than in cohorts initially managed medically, although much of the evidence is observational rather than from large randomised trials.

That distinction matters: favourable surgical results do not mean every cavernoma associated with a seizure should automatically be removed.

Lesionectomy and the haemosiderin rim

A basic surgical approach is lesionectomy: removal of the cavernous malformation itself.

Because the tissue immediately surrounding a cavernoma can contain haemosiderin, gliosis and other changes linked to epileptogenesis, surgeons may also consider removing haemosiderin-stained tissue when this can be done safely.

How much surrounding tissue should be removed depends heavily on location. Tissue near language, motor, sensory, visual or memory networks cannot simply be removed because it appears altered on imaging.

The operation therefore has to balance seizure control, haemorrhage risk and preservation of neurological function.

Temporal cavernomas can be more complicated

Temporal lobe cavernomas deserve particular attention because longstanding seizures can recruit a wider temporal epileptic network.

In some people, removing the cavernoma alone is enough. In others, especially after years of seizures, the epileptogenic network may extend into adjacent temporal structures.

This is one reason early specialist assessment can matter. The longer a structural lesion participates in recurrent seizures, the more complex the relationship between the lesion and the wider epileptic network may become.

Presurgical assessment can therefore include prolonged video-EEG, neuropsychological testing, detailed MRI and, in selected cases, additional functional or invasive investigations.

What if the cavernoma is in an eloquent area?

A cavernoma may sit close to cortex responsible for language, movement, sensation or vision.

Even when seizures are troublesome, surgery may carry neurological risk. In these situations the decision is not simply “seizures versus no seizures”. It is a balance between seizure burden, haemorrhage risk, medication effects, surgical accessibility and the potential consequences of damaging essential cortex.

Functional mapping and specialist neurosurgical planning can be crucial.

What if the cavernoma is deep or in the brainstem?

Deep and brainstem cavernomas are clinically important because of haemorrhage and focal neurological risks, but they are generally less likely to be the source of ordinary cortical epileptic seizures than supratentorial cortical cavernomas.

A seizure in somebody with a brainstem cavernoma should therefore not automatically be attributed to that lesion without appropriate evaluation.

Incidental cavernomas

Many cavernomas are discovered on imaging performed for another reason.

An incidental cavernoma does not mean epilepsy is inevitable. The current consensus literature indicates that first-ever seizure risk in incidentally identified cavernomas is relatively low compared with the recurrence risk once definite cavernoma-related epilepsy has developed.

This distinction helps prevent overdiagnosis. A structural abnormality can be real and still be unrelated to the symptoms that prompted the scan.

Familial cavernomas and epilepsy

People with familial cavernous malformation may have multiple lesions, making seizure attribution harder.

If epilepsy is suspected, EEG and detailed electroclinical correlation can help determine whether one particular cavernoma is the likely epileptogenic lesion.

When multiple lesions exist, surgery should not be aimed simply at whichever cavernoma looks largest or most striking on MRI. The target has to make neurological and epileptological sense.

Do cavernomas grow?

Cavernous malformations can change over time. Their apparent size can alter because of haemorrhage, organisation of blood products or other lesion changes, and people with familial disease may develop additional lesions.

However, change in MRI appearance does not necessarily parallel seizure activity. A person can have stable imaging and changing seizures, or changing imaging without a corresponding change in seizure frequency.

Seizure recurrence after surgery

Even after apparently complete removal of a cavernoma, some people continue to have seizures.

Possible explanations include an established epileptic network extending beyond the lesion, residual epileptogenic tissue, another lesion, or an incorrect assumption that the removed cavernoma was the source.

Continued seizures therefore deserve reassessment rather than being dismissed as evidence that surgery simply “failed”.

Can antiseizure medication be stopped after successful surgery?

Sometimes, but not automatically.

Withdrawal decisions depend on seizure freedom, duration of epilepsy before surgery, completeness of treatment, EEG findings, lesion location, recurrence risk and the person’s circumstances.

A person who becomes seizure-free after surgery may eventually discuss medication reduction with their specialist team, but there is no single timetable that is correct for everyone.

Cavernoma, DVA and other vascular findings

Cavernous malformations can occur alongside a developmental venous anomaly (DVA). A DVA is a different type of vascular structure and often represents important normal venous drainage for that region of brain.

This matters surgically because damaging a DVA can cause serious venous complications. The vascular anatomy around a cavernoma therefore has to be understood before intervention.

Pregnancy and inherited disease

Pregnancy, genetic counselling and family planning can be relevant for people with familial cavernous malformation and for anyone taking antiseizure medication.

The 2025/2026 consensus guideline recommends considering genetic counselling in people with familial or multifocal cavernous malformations, including before pregnancy.

Pregnancy decisions should be individualised with the relevant neurology, neurosurgical, obstetric and genetics teams where appropriate.

The key distinction

A cavernoma is a vascular structural lesion. Cavernoma-related epilepsy is the electrical network disorder that can develop around some of those lesions.

The two are connected, but they are not identical.

A cavernoma can exist without epilepsy. A seizure in somebody with a cavernoma may have another cause. A large lesion is not necessarily the epileptic lesion. A normal routine EEG does not exclude cavernoma-related epilepsy. And successful removal of the vascular lesion does not guarantee that an established epileptic network will immediately disappear.

The strongest diagnosis comes from agreement between clinical events, anatomy, EEG and the behaviour of the lesion over time.

Sources and further reading

Evidence checked: September 2026.

This page is for general education and does not replace individual advice from a neurologist, epilepsy specialist or neurosurgeon.